Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer's Disease Agitation
Stock Information for Axsome Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.